Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tourmaline Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
TRML
Nasdaq
2836
www.tourmalinebio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tourmaline Bio, Inc.
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
- Jan 27th, 2025 12:00 pm
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
- Jan 10th, 2025 12:30 pm
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
- Dec 10th, 2024 1:30 pm
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
- Nov 14th, 2024 12:30 pm
Tourmaline Bio, Inc. Reports Third Quarter Financial Results
- Nov 13th, 2024 4:00 am
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Nov 7th, 2024 12:30 pm
Tourmaline Bio to Present at Upcoming Investor Conferences
- Oct 31st, 2024 11:30 am
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
- Oct 15th, 2024 11:30 am
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
- Oct 11th, 2024 11:30 am
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
- Oct 8th, 2024 11:30 am
Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock
- Aug 8th, 2024 12:45 pm
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Aug 8th, 2024 11:30 am
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
- Aug 2nd, 2024 8:30 pm
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
- Jun 27th, 2024 12:05 pm
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
- May 23rd, 2024 11:10 am
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
- May 16th, 2024 11:00 am
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
- May 13th, 2024 11:00 am
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Apr 2nd, 2024 11:00 am
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Mar 19th, 2024 11:00 am
Scroll